Disease · MONDO_0006559
hidradenitis suppurativa
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hidradenitis suppurativa. Diseases, record MONDO_0006559. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006559
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Acne inversa, familial, HS, acne inversa, ectopic acne, fox den disease, hidradenitis, pyoderma fistulans significa, verneuil disease
- Open Targets
Drugs77
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ADALIMUMAB | CHEMBL1201580 | Antibody | Approval | EMA Human Drugs | 25 | 13 | 13 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| POVORCITINIB | CHEMBL5095079 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 7 | 7 | Drugs and targets |
| BIMEKIZUMAB | CHEMBL4297700 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| M-1095 | CHEMBL4298023 | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets | |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LUTIKIZUMAB | CHEMBL4594518 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| REMIBRUTINIB | CHEMBL4483575 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| IZOKIBEP | CHEMBL4297686 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 77
See all 77 drugsTargets106
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL17A | Interleukin-17A | 6 | Interleukin 17A binding agent; Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 6 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 3 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| IL12B | Interleukin-12 | 3 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 3 | Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TNF | Tumor necrosis factor | 3 | TNF-alpha inhibitor | Approval | https://conductscience.org/library/genes/7124 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| IL17F | Interleukin-17F | 2 | Interleukin-17F inhibitor | Phase 3 | https://conductscience.org/library/genes/112744 | Drugs and targets |
1 to 10 of 106
See all 106 targetsTrials123
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04179175 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | Phase 3 | 702 | 2024-06-21 | Hidradenitis Suppurativa | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03713632 | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) | Phase 3 | 545 | 2023-08-02 | Hidradenitis Suppurativa | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03713619 | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). | Phase 3 | 544 | 2024-09-25 | Hidradenitis Suppurativa | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04242498 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 3 | 509 | 2024-12-05 | Hidradenitis Suppurativa | BIMEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01635764 | Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | Phase 3 | 508 | 2017-09-05 | Hidradenitis Suppurativa | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04242446 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 3 | 505 | 2025-01-09 | Hidradenitis Suppurativa | BIMEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03852472 | Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) | Phase 2 | 435 | 2024-03-15 | Hidradenitis Suppurativa, Acne Inversa | AVACOPAN | Its record names the disease | ClinicalTrials.gov |
| NCT01468233 | Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa | Phase 3 | 326 | 2015-10-28 | Hidradenitis Suppurativa (HS) | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01468207 | Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa | Phase 3 | 307 | 2015-10-28 | Hidradenitis Suppurativa (HS) | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05905783 | Hidradenitis Suppurativa Study of Izokibep | Phase 3 | 258 | 2025-10-15 | Hidradenitis Suppurativa | IZOKIBEP | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 123
See all 123 trialsComparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adalimumab vs Placebo: deaths from any cause | 2 of 103 | 0 of 103 | 206 | NCT02808975 | Trial comparisons |
| Adalimumab vs Placebo: serious adverse events | 7 of 103 | 3 of 103 | 206 | NCT02808975 | Trial comparisons |
| MEDI8968 vs Saline: serious adverse events | 2 of 55 | 2 of 54 | 109 | NCT01838499 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: deaths from any cause | 0 of 66 | 0 of 35 | 101 | NCT05635838 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events | 2 of 66 | 1 of 35 | 101 | NCT05635838 | Trial comparisons |
| ATI-450 vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 35 of 48 | 26 of 47 | 95 | NCT05216224 | Trial comparisons |
| ATI-450 vs Placebo: deaths from any cause | 0 of 48 | 0 of 47 | 95 | NCT05216224 | Trial comparisons |
| ATI-450 vs Placebo: serious adverse events | 0 of 48 | 1 of 47 | 95 | NCT05216224 | Trial comparisons |
Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period | 13 of 34 | 15 of 35 | 69 | NCT05635838 | Trial comparisons |
| Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period | 0 of 34 | 2 of 35 | 69 | NCT05635838 | Trial comparisons |
1 to 10 of 27
See all 27 comparisons in its trialsPapers from its trials75
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006559
GET https://conductscience.org/api/diseases/v1/MONDO_0006559/drugs?page=2